Article of manufacture for instant release of anti-aggregation and non-thrombogenic agents to biological media

Claim 2

A novel article of manufacture wherein said article consists essentially of a biologically acceptable synthetic polymer having imbibed into its outermost surface and coated thereon a platelet aggregation inhibiting amount of prostaglandin that is easily released when contacted with blood, plasma and platelets and wherein the prostaglandin is a compound selected from those of the formulae: ##SPC10## wherein R 3 is a member selected from the group consisting of hydrogen and lower alkyl, R 4 is a member selected from the group consisting of hydrogen, lower alkyl and an acyl group of 2 to 18 carbons, R 5 is hydroxy, n is a whole integer of 3 to 5 inclusive, and the diastereomers thereof.

Claim 3

An article of manufacture according to claim 1 wherein the prostaglandin is 11α,15(S)-dihydroxy-9-oxo-13-trans-prostenoic acid.

Claim 4

An article of manufacture according to claim 1 wherein the prostaglandin is 11α,15(S)-dihydroxy-9-oxo-13-trans-8-isoprostenoic acid.

Claim 5

An article of manufacture according to claim 1 wherein the prostaglandin is 11α,15(S)-dihydroxy-9-oxo-13-trans-ω-homoprostenoic acid.

Claim 6

An article of manufacture according to claim 1 wherein the biologically acceptable synthetic polymer is shaped, silica-free and non-ionic, and wherein the prostaglandin is releasably, intimately physically deposited thereon, but chemically and ionically unbonded thereto, thus defining a prostaglandin reservoir responsive to the flow of liquid thereover.

Claim 7

An article of manufacture consisting essentially of a biologically acceptable synthetic polymer and wherein the polymer has at least one blood contacting surface rendered releasable to a non-thrombogenic agent and an anti-aggregation agent by having releasably incorporated into the polymeric surface and releasably coated thereon a coagulation inhibiting amount of a anti-thrombogenic agent and a platelet aggregation inhibiting amount of an anti-aggregation agent wherein the anti-thrombogenic agent is a member selected from the group consisting of heparin, coumarin, dicumarol and warfarin and wherein the anti-aggregation agent is a prostaglandin compound selected from those of the formulae: ##SPC11## wherein R 3 is a member selected from the group consisting of hydrogen and lower alkyl, R 4 is a member selected from the group consisting of hydrogen, lower alkyl and an acyl group of 2 to 18 carbons, R 5 is hydroxy, n is a whole integer of 3 to 5 inclusive, and the diastereomers thereof.

Claim 8

An article of manufacture consisting essentially of a biologically acceptable synthetic polymer and wherein the polymer has at least one blood contacting surface rendered releasable to a non-thrombogenic agent and an anti-aggregation agent by having releasably incorporated into the polymeric surface and releasably coated thereon a coagulation inhibiting amount of a anti-thrombogenic agent and a platelet aggregation inhibiting amount of an anti-aggregation agent wherein the anti-thrombogenic agent is a member selected from the group consisting of heparin, coumarin, dicumarol and warfarin and wherein the anti-aggregation agent is a prostaglandin compound selected from those of the formulae: ##SPC11## wherein R 3 is a member selected from the group consisting of hydrogen and lower alkyl, R 4 is a member selected from the group consisting of hydrogen, lower alkyl and an acyl group of 2 to 18 carbons, R 5 is hydroxy, n is a whole integer of 3 to 5 inclusive, and the diastereomers thereof.

Claim 9

An article of manufacture according to claim 6 wherein the anti-aggregation agent is 11α,15(S)-dihydroxy-9-oxo-13-trans-prostenoic acid.

Claim 10

An article of manufacture according to claim 6 wherein the anti-aggregation agent is 11α,15(S)-dihydroxy-9-oxo-13-trans-8-iso-prostenoic acid.

Claim 11

An article of manufacture according to claim 6 wherein the anti-aggregation agent is 11α15(S)-dihydroxy-9-oxo-13-trans-ω-homo-prostenoic acid.

Claim 12

An article of manufacture according to claim 6 wherein the anti-thrombogenic agent is heparin.

Claim 13

A process for essentially protecting blood, plasma and platelets against the platelet aggregation effects of a plastic surface when the blood, plasma and platelets are in contact with the plastic surface and also for simultaneously adding a platelet aggregation inhibiting agent to blood, plasma and platelets when in contact with the plastic surface, wherein the process consists essentially of rendering the plastic surface free from said effects by first coating the plastic surface with at least one anti-aggregation prostaglandin wherein the prostaglandin is a compound selected from those of the formulae: ##SPC12## wherein R 3 is a member selected from the group consisting of hydrogen and lower alkyl, R 4 is a member selected from the group consisting of hydrogen, lower alkyl and an acyl group of 2 to 18 carbons, R 5 is a hydroxy, n is a whole integer of 3 to 5 inclusive, and the diastereomers thereof, said prostaglandin being released from the coated surface in a platelet aggregation inhibiting amount to protect said blood, plasma and platelets against said platelet aggregation effects of the polymer upon contact therewith, while simultaneously adding the prostaglandin to the blood, plasma and platelets.

Claim 14

A process for essentially protecting blood, plasma and platelets against the platelet aggregation effects of a plastic surface when the blood, plasma and platelets are in contact with the plastic surface and also for simultaneously adding a platelet aggregation inhibiting agent to blood, plasma and platelets when in contact with the plastic surface, wherein the process consists essentially of rendering the plastic surface free from said effects by first coating the plastic surface with at least one anti-aggregation prostaglandin wherein the prostaglandin is a compound selected from those of the formulae: ##SPC12## wherein R 3 is a member selected from the group consisting of hydrogen and lower alkyl, R 4 is a member selected from the group consisting of hydrogen, lower alkyl and an acyl group of 2 to 18 carbons, R 5 is a hydroxy, n is a whole integer of 3 to 5 inclusive, and the diastereomers thereof, said prostaglandin being released from the coated surface in a platelet aggregation inhibiting amount to protect said blood, plasma and platelets against said platelet aggregation effects of the polymer upon contact therewith, while simultaneously adding the prostaglandin to the blood, plasma and platelets.